Abstract
Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have